Exploring Pulegone In Type 2 Diabetes Treatment: Molecular Docking, Influence On Insulin Resistance And Modulation Of Pro/Anti-Inflammatory Cytokines

Read full text Summarise with VIRAT
Authors: Rubina Muhammad Ali, Abdullah Abdo Albajali, Aisha Mobashar, Tahir Maqbool, Arham Shabbir, Kashif Barkat, Khalid Hussain
Cited by: 0
References: 48

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Type 2 diabetes involves insulin resistance, where muscle, liver, and fat cells fail to utilize glucose leading to hyperglycemia. OBJECTIVES: This study explores the therapeutic potential of pulegone in type 2 diabetes by examining its molecular interactions with key metabolic targets and evaluating its effects on insulin resistance and inflammatory cytokine modulation. METHODS: Except for normal controls, animals were fed a high-sucrose, high-fat diet for four months to induce insulin resistance. Treatment groups received metformin (150 mg/kg) or pulegone doses: low (5 mg/kg), medium (10 mg/kg), and high (15 mg/kg) for 45 days. Post-treatment, tissues and blood were collected. Blood serum was analyzed for liver markers, lipid profile, and blood for glycated hemoglobin. ELISA was used for cytokines (resistin, adiponectin, IL-1Ra, TNF-α), and qPCR assessed gene expression of NF-κB, TNF-α, PPAR-α/γ, IL-6, IL-10, IL-1Ra, and adiponectin. Histopathology was performed. Data were analyzed using GraphPad Prism. Molecular docking was conducted to identify the binding affinities of pulegone to target proteins. RESULTS: Pulegone significantly reduced fasting blood glucose, glycated hemoglobin, triglycerides, cholesterol, and liver enzymes, while increasing HDL levels compared with diabetic controls. It also decreased serum resistin, TNF-α, IL-6 and NF-κB expression, while upregulating adiponectin, IL-10, PPAR-α, PPAR-γ and IL-1Ra. Histopathological examination showed protective effects on the pancreas, liver, kidney, heart, and aorta. Docking analysis favored strong binding affinities of pulegone with key targets. CONCLUSION: Pulegone ameliorates insulin resistance by improving glycemic and lipid profiles, modulating pro- and anti-inflammatory cytokines, and protecting vital organs, suggesting its potential as a multitarget antidiabetic agent.

Fields of Study & Subjects

Natural Antidiabetic Agents Studies Adipokines Inflammation and Metabolic Diseases Diabetes Treatment and Management

Publication details

Journal / source
Pakistan Journal of Pharmaceutical Sciences
Volume
39
Issue
5
Pages
1326–1339
Publication date
5 March 2026
Language
EN